Breast Cancer Clinical Trials in Arizona

Showing 121-140 of 291 trials

FPA150 in Patients With Advanced Solid Tumors

NCT03514121

This is a multi-center study to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary efficacy of FPA150, an anti-B7H4 antibody alone or in combination with pembrolizumab an anti-PD1 antibody in patients with advanced solid tumors. The Phase 1a, open-label, cohort will identify a recommended dose of FPA150 to use for Phase 1a Combination (FPA150 and Pembrolizumab) Safety Lead-in and for Phase 1b monotherapy cohorts.

Breast CancerOvarian CancerEndometrial Cancer+1 more

Five Prime Therapeutics, Inc.95 participantsStarted Mar 2018

Scottsdale, Arizona, United States • Los Angeles, California, United States • Los Angeles, California, United States +15 more locations

ACTIVE_NOT_RECRUITING31 miles

Breast Cancer Index (BCI) Registry

NCT04875351

The purpose of the Breast Cancer Index (BCI) Registry study is to conduct a large scale, population-based prospective registry to evaluate long-term clinical outcome, clinical impact, medication adherence and quality of life in hormone receptor positive (HR+) early-stage breast cancer patients receiving BCI testing as part of routine clinical care to inform extended endocrine therapy.

Breast Cancer

Biotheranostics, Inc.3,465 participantsStarted Apr 2021

Daphne, Alabama, United States • Mobile, Alabama, United States • Mobile, Alabama, United States +102 more locations

FPA150 in Patients With Advanced Solid Tumors

Breast Cancer Index (BCI) Registry

Breast Cancer Trials in Other Cities

Study Comparing the Bioavailability of TAS-102 Tablets to an Oral Solution Containing Equivalent Amounts of FTD and TPI

Hypofractionated Radiation Therapy in Preventing Recurrence in Patients With Breast Cancer After Surgery

Study of NGM831 as Monotherapy and in Combination With Pembrolizumab or Pembrolizumab and NGM438 in Advanced or Metastatic Solid Tumors

Open-Label, Phase 1 Study to Evaluate Duration of Severe Neutropenia After Same-Day Dosing of Eflapegrastim in Patients With Breast-Cancer

A Study of ZN-c5 in Subjects With Breast Cancer

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer

PARP Inhibition for Triple Negative Breast Cancer (ER-/PR-/HER2-)With BRCA1/2 Mutations

A Bioequivalence Study Between the Proposed and Current Talazoparib Capsule Formulation and Food Effect Study for the Proposed Talazoparib Capsule Formulation in Participants With Advanced Solid Tumors

Testing the Addition of Immunotherapy With Hu5F9-G4 (Magrolimab) to the Usual PARP Inhibitor, Olaparib for Treatment of Metastatic or Recurrent Breast or Castrate-Resistant Prostate Cancer With BRCA Mutations

Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor Malignancies

Galinpepimut-S in Combination With Pembrolizumab in Patients With Selected Advanced Cancers

A Study to Evaluate the Safety and Efficacy of Ipatasertib in Combination With Atezolizumab and Paclitaxel or Nab-Paclitaxel in Participants With Locally Advanced or Metastatic Triple-Negative Breast Cancer

A Study to Learn About the Study Medicine (Called PF-07220060 in Combination With PF-07104091) In Participants With Breast Cancer and Solid Tumors

AN0025 and Pembrolizumab Combination in Advanced Solid Tumors

Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer

Milademetan in Advanced/Metastatic Solid Tumors

Study of ADCT-301 in Patients With Selected Advanced Solid Tumors

A Study of Ipatasertib Plus Palbociclib and Fulvestrant Versus Placebo Plus Palbociclib and Fulvestrant in Hormone Receptor Positive and HER2 Negative Locally Advanced Unresectable or Metastatic Breast Cancer

Other Conditions in Arizona